Continuous Subcutaneous Glucose Monitoring: A Descriptive Study of Its Use in Critical Patients

What this Trial Is About

Researchers are conducting a single-center, observational, descriptive, longitudinal, and prospective study to assess the occurrence of potential hypoglycemic events in patients admitted to the Intensive Care Unit (ICU) at HLA Moncloa Hospital. This study focuses on critically ill patients who often experience disturbances in blood sugar control due to stress, infections, fasting, and treatments. The study aims to document the incidence and rate of hypoglycemic events detected by continuous glucose monitoring (CGM) sensors during a four-year follow-up period. Patients admitted to the ICU who receive insulin treatment and have CGM sensors placed will be observed. These sensors record glucose levels every 5 minutes, helping detect potential hypoglycemia defined as glucose levels below 80 mg/dL. When the device signals a potential low glucose event, healthcare staff will confirm this by blood glucose testing and take appropriate actions following standard ICU protocols. The study collects detailed data, including treatments, glucose readings, and patient characteristics, to better understand hypoglycemia in critical care. Participants will have CGM sensors placed and will receive usual clinical care by their physicians. Data from the sensors and patient records will be reviewed at discharge or death to create a pseudonymized database stored securely for research. The study monitors glucose continuously, records alarms, and tracks responses to potential hypoglycemic events. The main outcome is measuring the cumulative incidence of potential hypoglycemia during ICU admission over four years, alongside secondary measures describing patient profiles, glycemic patterns, and treatment responses.

Continuous Subcutaneous Glucose Monitoring in Critical Patients